title: CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development.
abstract: CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as "CDP", has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy.
authors.affiliation: Cerulean Pharma Inc., 840 Memorial Drive, Cambridge MA 02139, USA.
authors.forename: Cissy
authors.initials: C
authors.lastname: Young
authors.forename: Thomas
authors.initials: T
authors.lastname: Schluep
authors.forename: Jungyeon
authors.initials: J
authors.lastname: Hwang
authors.forename: Scott
authors.initials: S
authors.lastname: Eliasof
references.citation: Bioorg Med Chem. 1998 May;6(5):551-62
references.pmid: 9629468
references.citation: Mol Pharm. 2004 May-Jun;1(3):183-93
references.pmid: 15981921
references.citation: Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11394-9
references.pmid: 19564622
references.citation: Cancer Chemother Rep. 1972 Aug;56(4):515-21
references.pmid: 5081595
references.citation: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references.pmid: 2946403
references.citation: Clin Cancer Res. 2009 Jul 1;15(13):4365-73
references.pmid: 19549776
references.citation: Bioconjug Chem. 2003 Sep-Oct;14(5):1007-17
references.pmid: 13129405
references.citation: Cancer Chemother Pharmacol. 2006 May;57(5):654-62
references.pmid: 16133526
references.citation: Cancer Res. 2004 Oct 1;64(19):6845-8
references.pmid: 15466170
references.citation: Cancer Res. 1992 Dec 15;52(24):6774-81
references.pmid: 1458465
references.citation: Curr Med Chem Anticancer Agents. 2004 Sep;4(5):429-34
references.pmid: 15379698
references.citation: Biochemistry. 1989 May 30;28(11):4629-38
references.pmid: 2548584
references.citation: J Med Chem. 1994 Jan 7;37(1):40-6
references.pmid: 8289200
references.citation: J Cell Mol Med. 2009 Sep;13(9A):2780-6
references.pmid: 19674190
references.citation: Ann N Y Acad Sci. 1996 Dec 13;803:213-23
references.pmid: 8993515
references.citation: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references.pmid: 18758474
references.citation: Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4
references.pmid: 1763060
references.citation: Cancer Chemother Rep. 1972 Oct;56(5):573-8
references.pmid: 4652588
references.citation: Anticancer Drugs. 2001 Feb;12(2):89-105
references.pmid: 11261892
references.citation: Biochim Biophys Acta. 1992 Jan 10;1103(1):94-100
references.pmid: 1309663
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1606-14
references.pmid: 16533788
references.citation: Biochemistry. 1994 Aug 30;33(34):10325-36
references.pmid: 8068669